JOINT VENTURE WITH YAFO CAPITAL, LTD.
With the idea to have representatives for licensing transactions in Europe and in China, FCF Life Sciences formed a joint venture with Yafo Capital, Ltd. in 2019. Together, we form a unique team to address the needs of our European and Asian clients. Our aim is to facilitate and guarantee a smooth partnering process.
Facts on Yafo Capital, Ltd.
- Shanghai based advisory firm
- Established network and access to leading 200+ Pharma and MedTech companies in Asia
- Team of 20+ professionals with banking and healthcare background
- ~20 completed transactions within the last five years
ACCESS CHINA FORUM
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable business development opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations.
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Valuation Monitor – Q3 2021”.
The FCF Valuation Monitor is a comprehensive valuation analysis for the German small / midcap market segment and is published by FCF on a quarterly basis.
Key insights of Q3 2021 are:
- All four major German indices have recovered from the market volatility in November 2020, following new lockdown measures, availability of vaccines and the loosening of lockdown restrictions across Europe in response to the Covid-19 pandemic
- The SDAX outperformed its German peers, gaining +29.0% over the last 12 months
- In the last 12 months, positive share price performances are seen across all industries with gains ranging from +28.8% (Softare sector) to +69.2% (Hightech / Advanced Machinery)
- Across all sectors, sales are expected to grow at 12.5% per annum between 2020 and 2023, while the Media & Entertainment, Renewable Products / Services and Internet Products / Services sectors show sales growth rates of above 20%
To access the full report, please click here.
If you are interested in exploring China licensing opportunities, please contact us: